I'm aware they want to start their commercial marketing campaign towards the end of 2021. My question is about PR to the average retail investor; TV interviews, news, radio.
I've said before that Bisantrene has a long and compelling narrative, perfect for a highlight piece on a news program.
While the marketing to big Pharma will secure a buyout, I wouldn't want a small MC to hamper those efforts. I certainly think that a strong SP will be necessary to achieving a fair acquisition value - increased awareness is one path to addressing that.
I'm aware they want to start their commercial marketing...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |